Filing Flows › uniQure N.V. (QURE) › Guidance & outlook
uniQure N.V. (QURE) guidance and outlook
uniQure N.V.'s 10-Q filed Nov 4, 2026 makes 11 forward-looking statements, 5 of them new and 3 no longer said since the filing before.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- new · We will be notified once the date and timelines have been finalized.
- new · We plan to initiate patient screening in the United States by the end of 2026.
- GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the “SEC”) we make assumptions, judgments and estimates that can have a significant impact on our net loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures.
- Our R&D expenses generally consist of costs incurred for the development of our target candidates, which include:
- new · Through the termination of the Genezen CSA in October 2026, we treated costs related to the purchase of HEMGENIX® from Genezen and revenue from the sales of HEMGENIX® to CSL Behring as an agent, and presented them on a net basis, together with income related to the release of liabilities associated with expected net losses, in Other expense within the Company's Consolidated Statements of Operations and…
- new · In the three months ended September 30, 2026 and September 30, 2025, we incurred costs related to research and technology projects of $3.2 million and $1.4 million, respectively, related primarily to our preclinical activities associated with product candidates for various other research programs and technology innovation projects.
- new · In the nine months ended September 30, 2026 and September 30, 2025, we incurred costs related to research and technology projects of $6.2 million and $3.1 million, respectively, related primarily to our preclinical activities associated with product candidates for various other research programs and technology innovation projects.
- We have based our estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect, and as such, we may require additional funding.
- updated · This includes up to $100.0 million in additional availability under our Hercules senior secured term loan facility, which becomes accessible upon BLA approval for ifezuntirgene inilparvovec prior to September 30, 2027, subject to confirmatory trial requirements remaining on track.
- As of September 30, 2026, we expect these obligations will become payable between 2030 and 2034.
- We also owe payments to a financial advisor related to certain payments we will collect under the CSL Behring Agreement.
uniQure N.V.'s latest quarter
uniQure N.V., Q3 2026: revenue $5.2M (+40% year over year), net loss $61.2M, operating cash flow −$47.8M. The chart follows the revenue to costs, profit and cash.
Questions
What does uniQure N.V. expect?
We will be notified once the date and timelines have been finalized. We plan to initiate patient screening in the United States by the end of 2026. Through the termination of the Genezen CSA in October 2026, we treated costs related to the purchase of HEMGENIX® from Genezen and revenue from the sales of HEMGENIX® to CSL Behring as an agent, and presented them on a net basis, together with income related to the release of liabilities associated with expected net losses, in Other expense within the Company's Consolidated Statements of Operations and…
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.